Literature DB >> 8865021

Multiple sclerosis: symptomatic treatment.

A J Thompson1.   

Abstract

Reports of new therapeutic agents designed to suppress inflammatory processes in multiple sclerosis have excited much interest but, thus far, have had little influence on symptoms, disability and handicap in patients. The clinical application of recent advances in physical, pharmacological and surgical approaches to management will, at least in the medium-term future, therefore offer significantly greater opportunities for improving the quality of life of patients with multiple sclerosis. Here, symptomatic treatment of the whole range of difficulties encountered by patients with multiple sclerosis is reviewed in the context of the multidisciplinary strategy crucial to an optimal outcome.

Entities:  

Mesh:

Year:  1996        PMID: 8865021     DOI: 10.1007/bf00900942

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  48 in total

1.  Intrathecal phenol to relieve spasticity in paraplegia.

Authors:  P W NATHAN
Journal:  Lancet       Date:  1959-12-19       Impact factor: 79.321

2.  Multiple sclerosis and the mind.

Authors:  M A Ron; A Feinstein
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-01       Impact factor: 10.154

3.  Botulinum toxin therapy for squint.

Authors:  J Lee; J Elston; S Vickers; C Powell; J Ketley; C Hogg
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

Review 4.  Investigation of the neurogenic bladder.

Authors:  C J Fowler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

5.  Treatment of paroxysmal symptoms in multiple sclerosis with bromocriptine.

Authors:  O A Khan; M J Olek
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

6.  Stereotactic thalamotomy for the relief of intention tremor of multiple sclerosis.

Authors:  J D Speelman; J Van Manen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-06       Impact factor: 10.154

7.  Sexual dysfunction in multiple sclerosis.

Authors:  M L Valleroy; G H Kraft
Journal:  Arch Phys Med Rehabil       Date:  1984-03       Impact factor: 3.966

8.  Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.

Authors:  C Smith; G Birnbaum; J L Carter; J Greenstein; F D Lublin
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

9.  Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres.

Authors:  R M Sherratt; H Bostock; T A Sears
Journal:  Nature       Date:  1980-02-07       Impact factor: 49.962

10.  Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition.

Authors:  C D Betts; S J Jones; C G Fowler; C J Fowler
Journal:  Brain       Date:  1994-12       Impact factor: 13.501

View more
  2 in total

1.  Incidence and predictive factors of depressive symptoms in Alzheimer's disease: the REAL.FR study.

Authors:  C Arbus; V Gardette; C E Cantet; S Andrieu; F Nourhashémi; L Schmitt; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

2.  Exploration of Undertreatment and Patterns of Treatment of Depression in Multiple Sclerosis.

Authors:  Aida Raissi; Andrew G M Bulloch; Kirsten M Fiest; Keltie McDonald; Nathalie Jetté; Scott B Patten
Journal:  Int J MS Care       Date:  2015 Nov-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.